Saturday 17 October 2026
Export AMWL’s income statement to Excel — free account
American Well Corporation
AMWL Healthcare Health Information Services
American Well Corporation’s revenue for fiscal 2025 (year ended December 2025) was $249.3 million, down 1.98% from fiscal 2024. In the quarter to June 2026, revenue fell 26.6%, EPS grew 52.4% and free cash flow grew 266.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
11.68
0.70
−5.65%
Follow AMWL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.70 | 0.37 | 0.32 | 0.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
14.26 | (88.77) | (4.54) | (5.31) | |
P/B ratio |
0.65 | 0.36 | 0.32 | 0.37 | |
Price to Tangible BV |
0.86 | 0.49 | 0.43 | 0.52 | |
EV/Sales |
(0.20) | (0.39) | (0.42) | (0.38) | |
EV/EBITDA |
0.96 | 1.68 | 1.53 | 1.18 | |
EV/Operating CF |
1.66 | 2.22 | 1.57 | 1.63 | |
EV/FCF |
1.37 | 2.08 | 1.57 | 1.57 | |
Quick Ratio |
2.73 | 2.83 | 3.17 | 2.97 | |
Current Ratio |
2.90 | 3.09 | 3.37 | 3.14 | |
Net Debt/EBITDA |
110.10 | 19.74 | 11.60 | 10.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.61 | 0.64 | 0.66 | 0.63 | |
Operating CF/Net income |
(1.08) | 0.09 | 0.70 | 0.58 | |
Capex/Depreciation |
(0.37) | (0.34) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
19.89% | 22.56% | 25.20% | 33.01% | |
Selling, General and Administrative Expense of Revenue |
37.94% | 46.36% | 56.15% | 54.75% | |
Intangible Assets out of Total Assets |
0.17 | 0.19 | 0.20 | 0.21 | |
Share Based Compensation of Revenue |
3.91% | 4.20% | 8.28% | 7.25% | |
Graham Net Nets |
1.12 | 1.98 | 2.17 | 1.80 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(52.30%) | (103.04%) | (121.18%) | (117.07%) | |
Free Cash Flow Yield |
(20.96%) | (51.14%) | (83.73%) | (64.64%) | |
Revenue per Share |
3.11 | 3.31 | 3.45 | 3.47 | |
Operating CF per Share |
0.64 | (0.06) | (1.08) | (1.16) | |
Capex per Share |
(0.17) | (0.17) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.47 | (0.23) | (1.08) | (1.16) | |
Cash per Share |
11.74 | 10.85 | 11.36 | 12.39 | |
Shareholders Equity per Share |
13.98 | 14.47 | 15.44 | 16.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.98 | 14.47 | 15.44 | 16.49 | |
Free Cash Flow |
7.86 | (3.77) | (17.37) | (18.77) | |
Working Capital |
173.43 | 175.28 | 173.47 | 184.68 | |
Capital Expenditures |
(2.86) | (2.79) | (0.01) | 0.00 | |
Net Current Asset Value |
171.82 | 173.21 | 170.68 | 179.11 | |
EV/EBIT |
0.54 | 1.00 | 0.98 | 0.82 | |
Capex to Sales |
0.05 | 0.05 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
53.08 | 64.55 | 60.79 | 72.42 | |
Average Payables |
2.71 | 3.91 | 3.33 | 7.06 | |
Average Inventory |
1.57 | 1.84 | 2.02 | 3.29 | |
Average Assets |
357.92 | 372.72 | 379.88 | 421.21 | |
Average Common Equity |
264.44 | 272.95 | 282.02 | 308.71 |
Columns are period end dates